Back

The efficacy and safety of apixaban use in chronic liver disease: a secondary analysis of the ARISTOTLE trial

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and stroke Stroke in Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Belal Suleiman

Duke University Medical Center, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail
Participation rate in opportunistic screening compared to systematic screening for atrial fibrillation: STROKESTOP III
Miss S. Skroder (Karlstad, SE)
Abstract Slides
Presentation thumbnail
A quantitative comparison of left- versus right-atrial intracardiac echocardiography for pulmonary vein visualization: a prospective single-center study
Doctor M. Pak (Kyoto, JP)
Abstract Slides
Presentation thumbnail
Pharmacologic and non-pharmacologic interventions for preventing postoperative atrial fibrillation in cardiac surgery: systematic review and network meta-analysis
Doctor C. Liu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Concurrent DOAC and rate control therapy in atrial fibrillation: nationwide time-dependent outcome analysis
Associate Professor R. Arbel (Tel Aviv, IL)
Abstract Slides
Presentation thumbnail
Ablation efficacy and safety in elderly vs. super-elderly with atrial fibrillation: insights from the prospective multicenter REAL-AF registry
Doctor C. Dai (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation and stroke

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
2 September 2019
thumbnail
Congress Presentation
Effectiveness of liver function tests in screening for cardiovascular risk in rheumatoid and psoriatic arthritis patients
12 December 2024
thumbnail
Congress Presentation
Non-alcoholic fatty liver disease in patients with atrial fibrillation: a report from a global federated health network.
8 April 2024
thumbnail
Congress Presentation
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources